Agios Pharma (AGIO) Tops Q4 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones
February 16, 2017 7:01 AM EST- Ivosidenib (AG-120) NDA Submission for IDH1m R/R AML Planned by Year End 2017; First Phase 1 Expansion Data Expected in the Second Half of 2017 -
- AG-348 Pivotal Trial Design Update Expected in the Third Quarter of 2017; Updated DRIVE PK Data Planned for the First Half of 2017 -
- MTAP Pathway IND Submission Expected by Year End 2017; Updated Preclinical Data to be Presented at Keystone Tumor Metabolism Meeting in March -
- Company Ends 2016 in Strong Financial Position with $574M in Cash, Cash Equivalents and... More
